Verve Therapeutics Inc Insiders are Selling. Investors Should Take Notice

GuruFocus data shows that Sekar Kathiresan, CEO of Verve Therapeutics Inc ( NA:VERV), sold 48.693 shares on December 28, 2021.

Verve Therapeutics Inc Insiders are Selling. Investors Should Take Notice
Verve Therapeutics Inc Insiders are Selling. Investors Should Take Notice

Insiders selling shares can cause investors concern. This could indicate that insiders have become bearish about the shares of their company's stock. Investors should pay close attention to insiders' ability to determine the company's value. We will take a closer look at Verve Therapeutics Inc's insider sale to determine if investors should be skeptical.

Sekar Kathiresan trades

Sekar Kathiresan sold 162,693 shares over the last year.

Sekar Kathiresan may have been selling the stock of their company over a more long-term. Contrary to what was expected, this could be a good sign for stock. Insiders selling frequently could indicate that their company has a large number of stock options for executives. Executives will sell some shares to raise cash. It is possible, however, that insiders became more bearish about the stock. Insider selling should not be taken lightly by investors.

Trends from the inside

One insider selling doesn't necessarily mean other insiders have a bearish view of the stock. Is the stock being sold by other insiders? Or have top company executives and owners bought more recently?

Verve Therapeutics Inc's insider transactions history shows that there were 8 insider buys over the last year. During the same period, 3 insider sales were also recorded.

Since this is a sign of a positive trend, we like to see insiders buying more than they are selling. Investors may not be concerned if more insiders buy the stock than they sell it.

Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.

This article first appeared on GuruFocus.